Jos Jonkers

List of Publications by Year in Descending Order

227 papers	22,552 citations	76 h-index	146 g-index
284 ext. papers	26,888 ext. citations	13.3 avg, IF	6.58 L-index

#	Paper	IF	Citations
227	Functional genetic dropout screens and validation of candidate therapeutic targets using mouse mammary tumoroids.. *STAR Protocols*, **2022**, 3, 101132	1.4	
226	Filling in the gaps in PARP inhibitor-induced synthetic lethality.. *Molecular and Cellular Oncology*, **2021**, 8, 2010512	1.2	0
225	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. *Molecular Cell*, **2021**, 81, 4692-4708.e9	17.6	8
224	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. *Cancers*, **2021**, 13,	6.6	3
223	Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum. *Cancers*, **2021**, 13,	6.6	3
222	SMARCAD1-mediated active replication fork stability maintains genome integrity. *Science Advances*, **2021**, 7,	14.3	10
221	PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair. *Cancers*, **2021**, 13,	6.6	2
220	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. *Nature Reviews Clinical Oncology*, **2021**, 18, 773-791	19.4	31
219	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. *Nature Genetics*, **2021**, 53, 86-99	36.3	44
218	The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice. *Current Opinion in Genetics and Development*, **2021**, 66, 57-62	4.9	6
217	Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. *Nature Communications*, **2021**, 12, 4360	17.4	4
216	Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. *Molecular Cell*, **2021**, 81, 3128-3144.e7	17.6	22
215	A BRCA1 coiled-coil domain variant disrupting PALB2 interaction promotes the development of mammary tumors and confers a targetable defect in homologous recombination repair. *Cancer Research*, **2021**,	10.1	1
214	Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate. *Molecular and Cellular Proteomics*, **2021**, 20, 100078	7.6	1
213	A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture. *Cancer Research*, **2021**,	10.1	2
212	Functional Categorization of Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays. *Clinical Cancer Research*, **2020**, 26, 4559-4568	12.9	6
211	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms. *Cancer Research*, **2020**, 80, 1486-1497	10.1	3

210	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. *OncoImmunology*, **2020**, 9, 1724049	7.2	6
209	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. *Science Translational Medicine*, **2020**, 12,	17.5	43
208	In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer. *EMBO Journal*, **2020**, 39, e102169	13	22
207	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. *Genes and Development*, **2020**, 34, 179-193	12.6	10
206	Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining. *Cell Reports*, **2020**, 32, 108068	10.6	8
205	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. *Nature Communications*, **2019**, 10, 397	17.4	31
204	GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice. *Journal of Mammary Gland Biology and Neoplasia*, **2019**, 24, 271-284	2.4	2
203	PARP Inhibitor Efficacy Depends on CD8 T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. *Cancer Discovery*, **2019**, 9, 722-737	24.4	222
202	EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. *Clinical Cancer Research*, **2019**, 25, 4351-4362	12.9	23
201	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. *Nature Cell Biology*, **2019**, 21, 511-521	23.4	73
200	Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin. *Nature Communications*, **2019**, 10, 3800	17.4	15
199	Ductal carcinoma in situ: to treat or not to treat, that is the question. *British Journal of Cancer*, **2019** , 121, 285-292	8.7	71
198	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. *Nature*, **2019**, 572, 538-542	50.4	173
197	Exogenous ER Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice. *Journal of Mammary Gland Biology and Neoplasia*, **2019**, 24, 305-321	2.4	0
196	Long-term expanding human airway organoids for disease modeling. *EMBO Journal*, **2019**, 38,	13	336
195	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors. *Cancer Research*, **2019**, 79, 452-460	10.1	26
194	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. *Annual Review of Cancer Biology*, **2019**, 3, 235-254	13.3	36
193	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. *Cell Reports*, **2018**, 23, 100-111	10.6	47

192	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. *Annals of Oncology*, **2018**, 29, 1203-1210	10.3	160
191	Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance. *Oncogene*, **2018**, 37, 1594-1609	9.2	5
190	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. *Cancer Discovery*, **2018**, 8, 498-515	24.4	51
189	Easy quantification of template-directed CRISPR/Cas9 editing. *Nucleic Acids Research*, **2018**, 46, e58	20.1	80
188	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2 *Laboratory Investigation*, **2018**, 98, 117-129	5.9	18
187	The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. *Cancer Cell*, **2018**, 34, 197-210.e5	24.3	82
186	The shieldin complex mediates 53BP1-dependent DNA repair. *Nature*, **2018**, 560, 117-121	50.4	277
185	Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents. *Molecular Oncology*, **2018**, 12, 953-971	7.9	7
184	Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. *British Journal of Cancer*, **2018**, 118, 1586-1595	8.7	16
183	Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547. *Cancer Research*, **2018**, 78, 5668-5679	10.1	27
182	Mouse models in the era of large human tumour sequencing studies. *Open Biology*, **2018**, 8,	7	7
181	BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. *Journal of Pathology*, **2018**, 246, 41-53	9.4	6
180	Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. *Cancer Cell*, **2018**, 33, 1078-1093.e12	24.3	139
179	BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. *Nature Methods*, **2018**, 15, 134-140	21.6	68
178	Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. *Cancer and Metastasis Reviews*, **2018**, 37, 577-597	9.6	86
177	The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. *Nature Communications*, **2018**, 9, 5406	17.4	49
176	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. *EMBO Molecular Medicine*, **2018**, 10,	12	85
175	XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. *BMC Bioinformatics*, **2018**, 19, 366	3.6	39

174	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. *Cell Reports*, **2018**, 23, 2107-2118	10.6	67
173	E-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer. *Journal of Pathology*, **2018**, 245, 456-467	9.4	15
172	Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nature Reviews Cancer*, **2017**, 17, 254-268	31.3	369
171	Genetically engineered mouse models in oncology research and cancer medicine. *EMBO Molecular Medicine*, **2017**, 9, 137-153	12	218
170	Identifying transposon insertions and their effects from RNA-sequencing data. *Nucleic Acids Research*, **2017**, 45, 7064-7077	20.1	5
169	Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. *Journal of Pathology*, **2017**, 241, 511-521	9.4	2
168	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. *Cancer Research*, **2017**, 77, e62-e66	10.1	65
167	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. *Nature Cell Biology*, **2017**, 19, 1371-1378	23.4	179
166	Selected Alkylating Agents Can Overcome Drug Tolerance of G-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. *Clinical Cancer Research*, **2017**, 23, 7020-7033	12.9	14
165	BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. *EMBO Molecular Medicine*, **2017**, 9, 1398-1414	12	39
164	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. *Nature Communications*, **2017**, 8, 15981	17.4	66
163	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. *Nature Genetics*, **2017**, 49, 1219-1230	36.3	49
162	Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. *Oncotarget*, **2017**, 8, 54364-54377	3.3	24
161	Intraductal cisplatin treatment in a -associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. *Oncotarget*, **2017**, 8, 60750-60763	3.3	4
160	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. *Oncotarget*, **2017**, 8, 87638-87646	3.3	7
159	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. *Cancer Research*, **2016**, 76, 6084-6094	10.1	50
158	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma. *Cell Reports*, **2016**, 16, 2087-2101	10.6	31
157	Replication fork stability confers chemoresistance in BRCA-deficient cells. *Nature*, **2016**, 535, 382-7	50.4	456

156	p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice. *Journal of Mammary Gland Biology and Neoplasia*, **2016**, 21, 81-88	2.4	9
155	Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. *Nature Cell Biology*, **2016**, 18, 1346-1356	23.4	49
154	Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer. *Cold Spring Harbor Symposia on Quantitative Biology*, **2016**, 81, 141-150	3.9	7
153	Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. *Genes and Development*, **2016**, 30, 1470-80	12.6	84
152	HELB Is a Feedback Inhibitor of DNA End Resection. *Molecular Cell*, **2016**, 61, 405-418	17.6	92
151	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors. *Clinical Cancer Research*, **2016**, 22, 96-106	12.9	39
150	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. *Journal of Clinical Investigation*, **2016**, 126, 2903-18	15.9	80
149	Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. *Oncotarget*, **2016**, 7, 63537-63548	3.3	13
148	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	108
147	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*, **2016**, 534, 47-54	50.4	1193
146	The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. *Cancer Research*, **2016**, 76, 2778-90	10.1	136
145	BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. *Cancer Research*, **2015**, 75, 732-41	10.1	36
144	Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. *Annals of Oncology*, **2015**, 26, 2180-92	10.3	72
143	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 8409-14	11.5	81
142	CopywriteR: DNA copy number detection from off-target sequence data. *Genome Biology*, **2015**, 16, 49	18.3	136
141	REV7 counteracts DNA double-strand break resection and affects PARP inhibition. *Nature*, **2015**, 521, 541-544	50.4	376
140	IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. *Nature*, **2015**, 522, 345-348	50.4	900
139	Using the GEMM-ESC strategy to study gene function in mouse models. *Nature Protocols*, **2015**, 10, 1755-1788	10.8	32

138	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. *International Journal of Cancer*, **2015**, 136, 1434-44	7.5	49
137	Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGF receptor I kinase. *Journal of Pathology*, **2015**, 235, 745-59	9.4	5
136	Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancer. *Pain*, **2015**, 156, 1424-1432	8	29
135	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. *Radiotherapy and Oncology*, **2015**, 116, 358-65	5.3	76
134	Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. *Cell Reports*, **2015**, 10, 383-397	10.6	54
133	The use of mass spectrometry imaging to predict treatment response of patient-derived xenograft models of triple-negative breast cancer. *Journal of Proteome Research*, **2015**, 14, 1069-75	5.6	22
132	BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres. *EMBO Journal*, **2015**, 34, 410-24	13	23
131	PARP Inhibitor Resistance What Is Beyond BRCA1 or BRCA2 Restoration?. *Cancer Drug Discovery and Development*, **2015**, 453-471	0.3	
130	Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. *Cell*, **2014**, 159, 499-513	56.2	542
129	Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discovery*, **2014**, 4, 998-1013	24.4	1018
128	Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. *Clinical Cancer Research*, **2014**, 20, 4816-26	12.9	111
127	Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. *Nature Biotechnology*, **2014**, 32, 1019-25	44.5	152
126	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. *Breast Cancer Research*, **2014**, 16, R47	8.3	70
125	Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases. *PLoS ONE*, **2014**, 9, e103177	3.7	9
124	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?. *Clinical Cancer Research*, **2014**, 20, 540-7	12.9	108
123	Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. *EMBO Molecular Medicine*, **2014**, 6, 212-25	12	71
122	Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 13427-32	11.5	62
121	Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells. *Oncotarget*, **2014**, 5, 11827-46	3.3	18

120	Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. *Scientific Reports*, **2013**, 3, 1949	4.9	18
119	Genetically engineered mouse models of PI3K signaling in breast cancer. *Molecular Oncology*, **2013**, 7, 146-64	7.9	28
118	ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. *Nature Communications*, **2013**, 4, 2697	17.4	30
117	BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. *Genes and Development*, **2013**, 27, 39-51	12.6	23
116	A preclinical mouse model of invasive lobular breast cancer metastasis. *Cancer Research*, **2013**, 73, 353-63	10.1	41
115	An Ë-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. *Journal of Pathology*, **2013**, 229, 621-9	9.4	138
114	Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal. *Stem Cells*, **2013**, 31, 1857-67	5.8	27
113	Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. *Cancer Discovery*, **2013**, 3, 68-81	24.4	346
112	A high-throughput functional complementation assay for classification of BRCA1 missense variants. *Cancer Discovery*, **2013**, 3, 1142-55	24.4	92
111	Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. *Cancer Research*, **2013**, 73, 4937-49	10.1	40
110	Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance. *Molecular and Cellular Proteomics*, **2013**, 12, 1319-34	7.6	19
109	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. *Journal of Experimental Medicine*, **2013**, 210, 1529-44	16.6	197
108	Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 8632-7	11.5	37
107	Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool. *Stem Cells*, **2013**, 31, 1910-20	5.8	37
106	Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors. *PLoS ONE*, **2013**, 8, e62113	3.7	13
105	Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS. *PLoS ONE*, **2013**, 8, e48324	3.7	17
104	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. *Journal of Cell Biology*, **2013**, 202, 2022OIA57	7.3	
103	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. *Cellular and Molecular Life Sciences*, **2012**, 69, 223-45	10.3	51

102	Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. *Gut*, **2012**, 61, 344-53	19.2	96
101	MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. *Breast Cancer Research*, **2012**, 14, 324	8.3	10
100	Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland. *Journal of Pathology*, **2012**, 228, 300-9	9.4	121
99	Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. *Current Opinion in Genetics and Development*, **2012**, 22, 21-7	4.9	22
98	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. *Nature Reviews Cancer*, **2012**, 12, 587-98	31.3	415
97	Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. *Molecular and Cellular Proteomics*, **2012**, 11, M111.013334	7.6	21
96	Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. *Nature Medicine*, **2012**, 18, 344-6; author reply 346	50.5	88
95	EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. *PLoS ONE*, **2012**, 7, e45248	3.7	21
94	Tracking evolution of BRCA1-associated breast cancer. *Cancer Discovery*, **2012**, 2, 486-8	24.4	2
93	Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol. *Cancer Prevention Research*, **2012**, 5, 1053-60	3.2	9
92	Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. *Nature*, **2012**, 482, 538-41	50.4	66
91	Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. *Cancer Research*, **2012**, 72, 2350-61	10.1	41
90	Abstract PR3: Patient derived BRCA1-deficient triple-negative breast cancer xenografts develop resistance to DNA damaging agents via genetic and epigenetic mechanisms. *Clinical Cancer Research*, **2012**, 18, PR3-PR3	12.9	
89	BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. *Cancer Cell*, **2011**, 20, 797-809	24.3	187
88	Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, **2011**, 16, 41-50	2.4	17
87	Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. *Journal of Pathology*, **2011**, 224, 56-66	9.4	20
86	Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. *Journal of Pathology*, **2011**, 224, 10-21	9.4	25
85	Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. *BioEssays*, **2011**, 33, 701-10	4.1	34

84	High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. *Genome Research*, **2011**, 21, 2181-9	9.7	36
83	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. *DMM Disease Models and Mechanisms*, **2011**, 4, 347-58	4.1	104
82	Computational identification of insertional mutagenesis targets for cancer gene discovery. *Nucleic Acids Research*, **2011**, 39, e105	20.1	21
81	Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. *Journal of Clinical Investigation*, **2011**, 121, 3176-88	15.9	85
80	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nature Structural and Molecular Biology*, **2010**, 17, 688-95	17.6	707
79	BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. *Nature Structural and Molecular Biology*, **2010**, 17, 1461-9	17.6	119
78	BRD7 is a candidate tumour suppressor gene required for p53 function. *Nature Cell Biology*, **2010**, 12, 380-9	23.4	161
77	Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. *Cancer Research*, **2010**, 70, 1700-10	10.1	67
76	A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. *Clinical Cancer Research*, **2010**, 16, 99-108	12.9	67
75	Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. *Cancer Research*, **2010**, 70, 520-31	10.1	27
74	Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach. *PLoS Computational Biology*, **2010**, 6, e1000631	5	18
73	Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. *Cell Cycle*, **2010**, 9, 3780-91	4.7	24
72	Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. *Cancer Research*, **2010**, 70, 883-95	10.1	36
71	A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. *Nanotechnology*, **2010**, 21, 355101	3.4	75
70	Targeting homologous recombination repair defects in cancer. *Trends in Pharmacological Sciences*, **2010**, 31, 372-80	13.2	81
69	Somatic structural rearrangements in genetically engineered mouse mammary tumors. *Genome Biology*, **2010**, 11, R100	18.3	22
68	Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. *BMC Cancer*, **2010**, 10, 455	4.8	31
67	BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. *BMC Cancer*, **2010**, 10, 654	4.8	46

66	KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data. *BMC Research Notes*, **2010**, 3, 298	2.3	21
65	Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model. *Applied Radiation and Isotopes*, **2010**, 68, 2117-24	1.7	6
64	A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. *Journal of Pathology*, **2010**, 220, 34-44	9.4	12
63	Studying drug resistance using genetically engineered mouse models for breast cancer. *Methods in Molecular Biology*, **2010**, 596, 33-45	1.4	9
62	Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. *Cancer Research*, **2009**, 69, 2244-51	10.1	61
61	Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 21836-41	11.5	20
60	Towards understanding the role of cancer-associated inflammation in chemoresistance. *Current Pharmaceutical Design*, **2009**, 15, 1844-53	3.3	36
59	Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. *Cancer Research*, **2009**, 69, 6396-404	10.1	79
58	CIP2A is associated with human breast cancer aggressivity. *Clinical Cancer Research*, **2009**, 15, 5092-100	12.9	190
57	High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. *Cancer Research*, **2009**, 69, 3625-33	10.1	120
56	Therapeutic options for triple-negative breast cancers with defective homologous recombination. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2009**, 1796, 266-80	11.2	22
55	Mammary tumorigenesis through LPA receptor signaling. *Cancer Cell*, **2009**, 15, 457-9	24.3	20
54	Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. *Journal of Pathology*, **2009**, 217, 597-604	9.4	15
53	A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. *Nature Protocols*, **2009**, 4, 789-98	18.8	128
52	BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. *Breast Cancer Research*, **2009**, 11, R63	8.3	86
51	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. *EMBO Journal*, **2008**, 27, 2603-15	13	157
50	Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. *Current Biology*, **2008**, 18, 1094-9	6.3	102
49	EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. *Breast Cancer Research*, **2008**, 10, R109	8.3	99

48	Modeling therapy resistance in genetically engineered mouse cancer models. *Drug Resistance Updates*, **2008**, 11, 51-60	23.2	27
47	Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. *Cell*, **2008**, 133, 727-41	56.2	149
46	Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. *Clinical Cancer Research*, **2008**, 14, 3916-25	12.9	258
45	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17079-84	11.5	707
44	Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. *Cell Cycle*, **2008**, 7, 2647-53	4.7	22
43	How do real tumors become resistant to cisplatin?. *Cell Cycle*, **2008**, 7, 1353-9	4.7	168
42	Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. *Nucleic Acids Research*, **2008**, 36, e13	20.1	59
41	Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. *Gastroenterology*, **2007**, 132, 1465-75	13.3	52
40	Models for angiogenesis: From fundamental mechanisms to anticancer treatment research. *Drug Discovery Today: Disease Models*, **2007**, 4, 75-82	1.3	
39	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. *Nature Genetics*, **2007**, 39, 759-69	36.3	148
38	Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. *Experimental Cell Research*, **2007**, 313, 133-45	4.2	60
37	Modeling metastatic breast cancer in mice. *Journal of Mammary Gland Biology and Neoplasia*, **2007**, 12, 191-203	2.4	53
36	What makes tumors multidrug resistant?. *Cell Cycle*, **2007**, 6, 2782-7	4.7	89
35	Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. *Physiological Genomics*, **2007**, 31, 32-41	3.6	142
34	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12111-6	11.5	343
33	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12117-22	11.5	241
32	Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. *Cancer Research*, **2007**, 67, 4648-56	10.1	38
31	Further evidence for BRCA1 communication with the inactive X chromosome. *Cell*, **2007**, 128, 991-1002	56.2	67

30	Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human. *American Journal of Pathology*, **2007**, 170, 377-87	5.8	16
29	Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. *Cancer Cell*, **2006**, 10, 437-49	24.3	466
28	Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. *Molecular and Cellular Biology*, **2006**, 26, 5015-22	4.8	432
27	Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. *FASEB Journal*, **2006**, 20, 953-5	0.9	25
26	Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. *Oncogene*, **2006**, 25, 5885-97	9.2	180
25	Human and mouse oligonucleotide-based array CGH. *Nucleic Acids Research*, **2005**, 33, e192	20.1	219
24	Frat is dispensable for canonical Wnt signaling in mammals. *Genes and Development*, **2005**, 19, 425-30	12.6	51
23	Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. *Cancer Research*, **2005**, 65, 8166-73	10.1	52
22	Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. *Molecular and Cellular Biology*, **2004**, 24, 6104-15	4.8	262
21	Characterization and functional analysis of the murine Frat2 gene. *Journal of Biological Chemistry*, **2004**, 279, 26967-74	5.4	14
20	Mutagenic insertion and chromosome engineering resource (MICER). *Nature Genetics*, **2004**, 36, 867-71	36.3	121
19	Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. *Oncogene*, **2004**, 23, 6047-55	9.2	54
18	Oncogene addiction: sometimes a temporary slavery. *Cancer Cell*, **2004**, 6, 535-8	24.3	56
17	A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. *Genome Research*, **2004**, 14, 188-96	9.7	55
16	Conditional mouse models of sporadic cancer. *Nature Reviews Cancer*, **2002**, 2, 251-65	31.3	242
15	Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. *Cancer Research*, **2002**, 62, 1862-7	10.1	135
14	Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nature Genetics*, **2001**, 29, 418-25	36.3	807
13	Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 9209-14	11.5	451

12	A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. *EMBO Reports*, **2001**, 2, 292-7	6.5	286
11	Mouse models for sporadic cancer. *Experimental Cell Research*, **2001**, 264, 100-10	4.2	28
10	Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. *Oncogene*, **1999**, 18, 5982-90	9.2	31
9	In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3. *Mechanisms of Development*, **1999**, 88, 183-94	1.7	34
8	Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. *EMBO Journal*, **1999**, 18, 4233-40	13	325
7	Identification and Characterization of Collaborating Oncogenes in Compound Mutant Mice **1998**, 15-30		
6	Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. *EMBO Journal*, **1997**, 16, 441-50	13	101
5	Retroviral insertional mutagenesis as a strategy to identify cancer genes. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1996**, 1287, 29-57	11.2	92
4	Glucocorticoids regulate cancer cell dormancy		3
3	PARPi synthetic lethality derives from replication-associated single-stranded DNA gaps		8
2	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts		2
1	MYC promotes immune-suppression in TNBC via inhibition of IFN signaling		1